XNASCING
Market cap15mUSD
Dec 31, Last price
4.93USD
1D
-1.00%
1Q
2.49%
IPO
-94.46%
Name
Cingulate Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-24m
L+31.85%
CFO
-15m
L-5.34%
Profile
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 22,759 | 18,124 | |||
Unusual Expense (Income) | |||||
NOPBT | (22,759) | (18,124) | |||
NOPBT Margin | |||||
Operating Taxes | 174 | ||||
Tax Rate | |||||
NOPAT | (22,759) | (18,298) | |||
Net income | (23,535) 31.85% | (17,850) -13.94% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 6,971 | (86) | |||
BB yield | -1,207.95% | 0.71% | |||
| Debt | |||||
Debt current | 3,000 | 5,016 | |||
Long-term debt | 645 | 1,037 | |||
Deferred revenue | |||||
Other long-term liabilities | 325,801 | ||||
Net debt | 3,593 | 696 | |||
| Cash flow | |||||
Cash from operating activities | (15,035) | (15,883) | |||
CAPEX | (153) | ||||
Cash from investing activities | (224) | (153) | |||
Cash from financing activities | 9,955 | 4,899 | |||
FCF | (14,973) | (17,119) | |||
| Balance | |||||
Cash | 52 | 5,356 | |||
Long term investments | |||||
Excess cash | 52 | 5,356 | |||
Stockholders' equity | (92,943) | (69,407) | |||
Invested Capital | 89,209 | 331,326 | |||
ROIC | |||||
ROCE | 609.46% | ||||
| EV | |||||
Common stock shares outstanding | 75 | 602 | |||
Price | 7.65 -61.75% | 20.00 -63.77% | |||
Market cap | 577 -95.21% | 12,047 -61.41% | |||
EV | 4,170 | 12,743 | |||
EBITDA | (22,176) | (17,730) | |||
EV/EBITDA | |||||
Interest | 174 | ||||
Interest/NOPBT | |||||